File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting

TitleSurvival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting
Authors
Kwok, WCHo, JCMTam, CCTIp, MSMLam, CLD
Issue Date2022
Citation
Thoracic Cancer, 2022, v. 13, p. 2057-2063 How to Cite?
DOI: http://dx.doi.org/10.1111/1759-7714.14528
Persistent Identifierhttp://hdl.handle.net/10722/315602
ISI Accession Number ID
WOS:000806587900001

 

DC FieldValueLanguage
dc.contributor.authorKwok, WC-
dc.contributor.authorHo, JCM-
dc.contributor.authorTam, CCT-
dc.contributor.authorIp, MSM-
dc.contributor.authorLam, CLD-
dc.date.accessioned2022-08-19T09:00:57Z-
dc.date.available2022-08-19T09:00:57Z-
dc.date.issued2022-
dc.identifier.citationThoracic Cancer, 2022, v. 13, p. 2057-2063-
dc.identifier.urihttp://hdl.handle.net/10722/315602-
dc.languageeng-
dc.relation.ispartofThoracic Cancer-
dc.titleSurvival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting -
dc.typeArticle-
dc.identifier.emailKwok, WC: kwokwch@hku.hk-
dc.identifier.emailHo, JCM: jhocm@hku.hk-
dc.identifier.emailIp, MSM: msmip@hku.hk-
dc.identifier.emailLam, CLD: dcllam@hku.hk-
dc.identifier.authorityKwok, WC=rp02966-
dc.identifier.authorityHo, JCM=rp00258-
dc.identifier.authorityIp, MSM=rp00347-
dc.identifier.authorityLam, CLD=rp01345-
dc.identifier.doi10.1111/1759-7714.14528-
dc.identifier.hkuros335856-
dc.identifier.volume13-
dc.identifier.spage2057-
dc.identifier.epage2063-
dc.identifier.isiWOS:000806587900001-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats